Content area
Full Text
[Image omitted] - (http://www.fiercebiotech.com/story/sunesis-plummets-fda-sends-it-back-drawing-board/2015-07-24)
Sunesis CEO Daniel Swisher
Despite its lead drug's failure in a late-stage trial last year, Sunesis Pharmaceuticals ($SNSS) held on to hope that it could convince the FDA to give the leukemia treatment a shot at approval. But its argument apparently fell on deaf ears, as the agency asked to see more clinical data before evaluating the therapy.
Sunesis' drug, vosaroxin is a derivative of the antibacterial agent quinolone designed to treat the rare acute myeloid leukemia. In...